CMS Non-Coverage Ruling Delay Apt If Device Lacks Evidence – AdvaMed
This article was originally published in The Gray Sheet
Executive Summary
CMS should defer to local carriers when an absence of data prevents the agency from discerning whether an item or service meets the standard for "reasonable and necessary," AdvaMed contends
You may also be interested in...
CMS Launches NCD Track For “Aggrieved” Parties With 90-Day Timeframe
CMS will implement a separate track with stricter deadlines for "aggrieved parties" to request national coverage determinations (NCDs), effective Oct. 27
NCD Process Pitfall: Being Dragged Into Review Before Data Are Ready
Allowing manufacturers to delay national coverage determinations in order to gather sufficient evidence would protect firms forced to undergo review under another company's request, AdvaMed says
AHRQ Brain Tumor MRS Tech Assessment Makes NCD Reversal Doubtful
The limited availability of magnetic resonance spectroscopy (MRS) for diagnosing brain tumors has made it difficult to pursue the types of large clinical trials necessary for obtaining national coverage, according to an 1AHRQ tech assessment